Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome) within 28 days prior to registration
Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome or if liver metastases are present)
Total bilirubin of ? 2.0 mg/dL (? 3.0 mg/dL for patients with known Gilbert's syndrome)
Bilirubin >1.5 mg/dL, except for Gilbert's Syndrome or hemolysis.
Total bilirubin <2.0 mg/dL unless elevated due to known Gilbert's syndrome.
Total bilirubin < 2.0 mg/dl (unless attributable to Gilbert's disease)
Total bilirubin ?1.5 mg/dL unless elevated due to known Gilbert's syndrome.
Have a total bilirubin level ?2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)
Total bilirubin ?1.5 mg/dL not related to hemolysis or Gilbert's disease
Total bilirubin (TBL) ? 2.5 mg/dL, except for participants with Gilbert's syndrome.
TBL < 2.5 mg/dL, except for participants with Gilbert's syndrome.
A bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease
Direct bilirubin must be < 2 mg/dL unless the elevation is known to be due to Gilbert syndrome within 3 days prior to enrollment.
Total bilirubin < 2.0 mg/dL (? 3.0 mg/dL for patients with known Gilbert's syndrome)
Bilirubin < 2.5 mg/dL (unless due to Gilbert's disease)
Total bilirubin < 1.5 mg/dL (or =< 3.0 mg/dL in patients with Gilbert syndrome)
A bilirubin of up to 2.0 mg/dL, excluding patients with Gilbert's disease
Direct bilirubin must be < 2 mg/dL unless the elevation is known to be due to Gilbert's syndrome or acute GVHD (aGVHD) within 3 days of enrollment
Patients with Gilbert syndrome are excluded from the requirement of a normal bilirubin but they must have an indirect bilirubin of < 6 mg/dl, and a direct bilirubin of < 0.5 mg/dl in order to be eligible; (Gilbert syndrome is found in 3-10% of the general population and is characterized by mild, chronic hyperbilirubinemia in the absence of liver disease or overt hemolysis)
Bilirubin (Gilbert's Disease) =< 3.0 mg/dL
Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome)
Patients must have a bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's)
Have a total bilirubin level ?2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)
Total bilirubin >= 2.0 mg/dl in the absence of a history of Gilbert's disease
Bilirubin =< 2.0 mg/dl, unless known Gilbert's syndrome
Serum total bilirubin < 2 mg/dl (except if known Gilbert syndrome AND normal transaminases)
Total bilirubin ? 2.0 mg/dL not related to hemolysis or Gilbert's disease.
Total bilirubin =< 2 mg/dL (=< 3 mg/dL in case of Gilbert's syndrome)
Bilirubin < 1.5 mg/dL, with the exception of patients thought to have Gilbert's syndrome, who may have a total bilirubin above 1.5 mg/dL
Total bilirubin =< 1.5 mg/dL (25.65 umol/L) (except patients with Gilbert's disease)
Serum bilirubin > 2.0 mg/dl (except in the case of Gilbert syndrome or ongoing hemolytic anemia)
Total bilirubin ? 2.0 mg/dL not related to Gilbert's disease or hemolysis.
Patients must have adequate organ and marrow function defined as: absolute neutrophil count (ANC) >/= 1,000/mL, platelets >/=75,000/mL; creatinine clearance >/= 35 ml/min; total bilirubin </= 2 X ULN (exceptions may apply to benign non-malignant indirect hyperbilirubinemia such as Gilbert syndrome); ALT (SGPT) and or AST (SGOT) </= 5 X ULN Exception for patients with liver metastasis: total bilirubin </= 3 x ULN; ALT (SGPT) </= 8 X ULN; Fasting lipid profile: cholesterol </= 350 mg/dL; triglycerides </= 400 mg/dL Corrected calcium >/= 8.4 mg/dL; phosphorus >/= 2.5 mg/dL for denosumab
Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome)
Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome)
Alanine aminotransferase ? 5 × ULN and total bilirubin < 2.0 mg/dL (or < 3.0 mg/dL for subjects with Gilbert's syndrome or leukemic infiltration of the liver)
Total bilirubin > 2.0 mg/dL (or > 3.0 mg/dL in participants with documented Gilbert syndrome)
Serum total bilirubin < 2.0 mg/dL, patients with Gilbert's Syndrome should contact the medical monitor
Total serum bilirubin must be < 3 mg/dL unless the elevation is thought to be due to Gilbert's disease or hemolysis
Serum bilirubin < 2 mg/dL (unless due to Gilbert's syndrome)
Bilirubin < 2.0 mg/dl (unless attributed to Gilbert's disease)
Total bilirubin =< 1.5 mg/dl unless felt secondary to Gilbert's disease
Serum direct bilirubin < 1.5 mg/dL (unless Gilbert's syndrome)
Serum direct bilirubin < 1.5 mg/dL (unless Gilbert's syndrome)
Hepatic: Bilirubin ? 2.5 mg/dL (except in the case of Gilbert's syndrome or ongoing hemolytic anemia); and ALT, AST and Alkaline Phosphatase ? 5 × ULN.
total bilirubin of ? 2.0 mg/dl (? 3.0 mg/dl for patients with known Gilbert's syndrome)
Patient must have adequate hepatic function documented by a total bilirubin of ? 2.0 mg/dl (? 3.0 mg/dl for patients with known Gilbert's syndrome) and ALT and AST ? 3 times the ULN for the reference lab.
Total bilirubin =< 1.5 mg/dL (unless there is a known history of Gilbert's syndrome)
Bilirubin =< 1.5 mg/dl (unless Gilbert's syndrome)
Patients must have a serum bilirubin equal to or =< 2.0 mg/dl (isolated hyperbilirubinemia related to Gilbert's disease allowed)
Serum direct bilirubin >= 1 mg/dl (except Gilbert's syndrome or hemolysis)
At the discretion of the operating surgeon, bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert’s)
At the discretion of the physician, bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's)
